Summit Therapeutics Stock Price, News & Analysis (NASDAQ:SMMT) $2.19 -0.03 (-1.35%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$2.17▼$2.2550-Day Range$1.67▼$2.4652-Week Range$1.25▼$5.78Volume701,103 shsAverage Volume970,956 shsMarket Capitalization$1.53 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesNovember 7, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023November 7, 2023 | finance.yahoo.comSummit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational ProgressDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 2, 2023 | finance.yahoo.comIvonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023November 1, 2023 | bizjournals.comFormer Reata Pharmaceuticals CFO steps into new role with California biotech companyOctober 31, 2023 | finance.yahoo.comIvonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023October 26, 2023 | finance.yahoo.comSummit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023October 19, 2023 | finance.yahoo.comH. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical DevelopmentDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 17, 2023 | finance.yahoo.comInsider Buying: COO Manmeet Soni Acquires 2,976,190 Shares of Summit Therapeutics IncSeptember 26, 2023 | msn.comSummit Therapeutics: Not For Retail InvestorsSeptember 25, 2023 | seekingalpha.comNavigating Summit Therapeutics' Bispecific Bet Amid Cash ConstraintsAugust 9, 2023 | finance.yahoo.comQ2 2023 Summit Therapeutics Inc Earnings CallAugust 9, 2023 | seekingalpha.comSummit Therapeutics, Inc. (SMMT) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023August 2, 2023 | finance.yahoo.comSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023July 11, 2023 | finance.yahoo.comSummit Therapeutics Insiders Up US$558m On US$517m InvestmentJune 4, 2023 | finance.yahoo.comPromising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023June 1, 2023 | finance.yahoo.comIvonescimab Updated Data to be Featured at ASCO 2023May 22, 2023 | finance.yahoo.com11 Stocks with Heavy Insider Buying in 2023May 18, 2023 | finance.yahoo.comAfter buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2bMay 16, 2023 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call TranscriptMay 16, 2023 | finance.yahoo.comWhy Shares of Summit Therapeutics Slumped on TuesdayMay 12, 2023 | finance.yahoo.comQ1 2023 Summit Therapeutics Inc Earnings CallMay 11, 2023 | seekingalpha.comSummit Therapeutics, Inc. (SMMT) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finance.yahoo.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023April 13, 2023 | seekingalpha.comSummit Therapeutics: Another Billionaire Project That Isn't Going AnywhereSee More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,780,000.00 Net MarginsN/A Pretax Margin-271,685.00% Return on Equity-64.01% Return on Assets-22.31% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$700,000.00 Price / Sales2,192.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book3.65Miscellaneous Outstanding Shares700,840,000Free Float114,237,000Market Cap$1.53 billion OptionableOptionable Beta-0.97 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 53)M.B.A., Co-CEO, President & Director Comp: $934.85kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $668.39kMr. Manmeet Singh Soni (Age 45)COO & Director Dr. Urte Gayko Ph.D. (Age 52)Chief Regulatory, Quality & Pharmacovigilance Officer? Prof. Dame Kay Davies DBE (Age 72)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Shelley D. Spray (Age 58)Head of Corporate Education, Communications & Creative? Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 55)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?More ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXDynavax TechnologiesNASDAQ:DVAXIronwood PharmaceuticalsNASDAQ:IRWDPTC TherapeuticsNASDAQ:PTCTHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 11,696 shares on 11/24/2023Ownership: 0.009%Legal & General Group PlcBought 7,480 shares on 11/15/2023Ownership: 0.017%The Manufacturers Life Insurance Company Bought 21,149 shares on 11/15/2023Ownership: 0.010%Sectoral Asset Management Inc.Sold 30,000 shares on 11/15/2023Ownership: 0.003%AQR Capital Management LLCBought 19,225 shares on 11/15/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed in 2023? Summit Therapeutics' stock was trading at $4.25 on January 1st, 2023. Since then, SMMT stock has decreased by 48.5% and is now trading at $2.19. View the best growth stocks for 2023 here. When is Summit Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our SMMT earnings forecast. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company earned $0.27 million during the quarter. What ETFs hold Summit Therapeutics' stock? ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP). When did Summit Therapeutics IPO? (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Summit Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.15%), Charles Schwab Investment Management Inc. (0.13%), Shell Asset Management Co. (0.05%), California State Teachers Retirement System (0.02%), Barclays PLC (0.02%) and Rhumbline Advisers (0.02%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SMMT) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.